TGA issued a recall for Nature's Own Glucosamine Sulfate with Chondroitin (320 pack) batch 1662937 and Nature's Own Magnesium Glycinate 1150mg (300 pack) batch 1665576 due to potential glass fragments.
Consumption of affected product may cause injury from glass fragments.
Stop using affected batches; return to place of purchase for full refund.
Regulatory Intelligence Lead
Review in the next regulatory intelligence cycle.
Stop using the products from the affected batches. Return the product to the place of purchase for a full refund.
Stop using affected batches; return to place of purchase for full refund.
TGA recalls two Sanofi-Aventis supplements due to glass fragments in batches 1662937 and 1665576.
What changed: TGA issued a recall for Nature's Own Glucosamine Sulfate with Chondroitin (320 pack) batch 1662937 and Nature's Own Magnesium Glycinate 1150mg (300 pack) batch 1665576 due to potential glass fragments.
Why it matters: Consumption of affected product may cause injury from glass fragments.
Practical implication: Stop using affected batches; return to place of purchase for full refund.
Published from the Firecrawl agent regulatory extraction pipeline.
Implement a gap analysis for 505(b)(2) applications to identify safety data needs and adjust safety monitoring systems as necessary to accommodate new product characteristics.
MAHs and sponsors must enhance their pharmacovigilance systems to monitor microbiome-specific safety issues, comply with established safety standards, and address concerns related to antimicrobial resistance.
Stakeholders, including manufacturers and clinicians, must review and potentially revise their post-market vigilance and safety monitoring protocols in response to the FDA's proposed regulatory approaches for generative AI devices.
Developers of MBMPs must align their safety assessment protocols with the MHRA's expectations and are encouraged to engage with the MHRA early to establish appropriate regulatory strategies.
